Bénard-Laribière Anne, Pariente Antoine
University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team Pharmacoepidemiology, UMR 1219, 33076 Bordeaux, France; DRUGS-SAFE National Platform of Pharmacoepidemiology, 33076 Bordeaux, France.
University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team Pharmacoepidemiology, UMR 1219, 33076 Bordeaux, France; DRUGS-SAFE National Platform of Pharmacoepidemiology, 33076 Bordeaux, France; University Hospital of Bordeaux, Clinical Pharmacology, 33076 Bordeaux, France.
Presse Med. 2018 Oct;47(10):878-881. doi: 10.1016/j.lpm.2018.10.005. Epub 2018 Oct 25.
Benzodiazepine use remains high in France in 2015, especially among the elders. However, encouraging trend is observed regarding hypnotic benzodiazepines initiation: between 2008 and 2015, incident use of hypnotics, including that of Z-drugs, decreased while incident use of anxiolytics remained stable. Most of new benzodiazepine users (86 %) had treatment duration that complies with guidelines. Owing to the high number of user initiating a treatment each year and associated risks, the remaining 14 % of long-term users is of concern. Roughly half of benzodiazepine users presented with comorbidities and concurrent medications increasing the risk of adverse drug reactions, especially central nervous system depressant effects.
2015年，法国苯二氮䓬类药物的使用量仍然很高，尤其是在老年人中。然而，在催眠性苯二氮䓬类药物的起始使用方面观察到了令人鼓舞的趋势：在2008年至2015年期间，包括Z类药物在内的催眠药的新使用量有所下降，而抗焦虑药的新使用量保持稳定。大多数新的苯二氮䓬类药物使用者（86%）的治疗持续时间符合指南。由于每年开始治疗的使用者数量众多以及相关风险，其余14%的长期使用者令人担忧。大约一半的苯二氮䓬类药物使用者患有合并症并同时使用多种药物，这增加了药物不良反应的风险，尤其是中枢神经系统抑制作用。
